Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nitric Oxide Releasing Sinus Irrigation (NOSi) is a topical therapeutic developed by SaNOtize Research and Development Corp. for the treatment of recalcitrant chronic rhinosinusitis (CRS), particularly cases associated with bacterial biofilms. The treatment utilizes SaNOtize's proprietary Nitric Oxide Releasing Solution (NORS) technology, which generates therapeutic concentrations of nitric oxide (NO) upon administration. Nitric oxide is a potent, broad-spectrum antimicrobial agent that exerts its effects by inducing oxidative and nitrosative stress, leading to the destruction of microbial DNA, proteins, and lipids. Crucially, NOSi is designed to penetrate and disrupt biofilms—structured communities of bacteria that are typically resistant to conventional antibiotics and host immune responses. The therapy is administered as a sinus irrigation, providing both mechanical cleansing of the sinus cavities and targeted chemical eradication of persistent pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nitric Oxide Releasing Sinus Irrigation.